Rigel Pharmaceuticals (RIGL) to Release Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is expected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Rigel Pharmaceuticals to post earnings of $1.17 per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:00 PM ET.

Rigel Pharmaceuticals Stock Performance

Shares of NASDAQ:RIGL opened at $34.26 on Tuesday. The company has a current ratio of 2.28, a quick ratio of 2.14 and a debt-to-equity ratio of 0.25. Rigel Pharmaceuticals has a 12 month low of $15.50 and a 12 month high of $52.24. The company has a market capitalization of $621.82 million, a price-to-earnings ratio of 5.55 and a beta of 1.11. The firm’s 50-day moving average is $38.72 and its 200 day moving average is $37.48.

Institutional Trading of Rigel Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in RIGL. Bank of Montreal Can purchased a new stake in shares of Rigel Pharmaceuticals during the 4th quarter worth $208,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Rigel Pharmaceuticals by 14.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,366 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 1,464 shares in the last quarter. Jain Global LLC purchased a new stake in shares of Rigel Pharmaceuticals during the third quarter valued at about $201,000. AQR Capital Management LLC purchased a new stake in shares of Rigel Pharmaceuticals during the first quarter valued at about $191,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Rigel Pharmaceuticals in the 2nd quarter valued at about $178,000. 66.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on RIGL shares. Citigroup reaffirmed a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, January 14th. Zacks Research raised Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 18th. Cantor Fitzgerald increased their target price on Rigel Pharmaceuticals from $32.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Rigel Pharmaceuticals presently has an average rating of “Hold” and an average price target of $43.20.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).